{"nctId":"NCT01303796","briefTitle":"A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia","startDateStruct":{"date":"2011-10-01","type":"ACTUAL"},"conditions":["Acute Myeloid Leukemia"],"count":482,"armGroups":[{"label":"Sapacitabine-decitabine alternating","type":"EXPERIMENTAL","interventionNames":["Drug: Sapacitabine","Drug: Decitabine"]},{"label":"Decitabine","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Decitabine"]}],"interventions":[{"name":"Sapacitabine","otherNames":["CYC682"]},{"name":"Decitabine","otherNames":["Decitabine intravenous"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Newly diagnosed AML based on WHO (World Health Organization) classification\n* Age 70 years or older for whom the treatment of choice is low-intensity therapy by investigator assessment or who has refused intensive induction therapy recommended by investigator\n* ECOG (Eastern Cooperative Oncology Group) performance status 0-2\n* Adequate renal function\n* Adequate liver function\n* Able to swallow capsules\n* Agree to practice effective contraception\n* Ability to understand and willingness to sign the informed consent form\n\nExclusion Criteria:\n\n* AML is of the sub-type of acute promyelocytic leukemia or extramedullary myeloid tumor without bone marrow involvement\n* Having received any systemic anti-cancer therapy for AML or received treatment with hypomethylating agents or cytotoxic chemotherapy for preceding myelodysplastic syndrome (MDS) or myeloproliferative disease (MPD)\n* Known or suspected central nervous system (CNS) involvement by leukemia\n* Uncontrolled intercurrent illness\n* Known hypersensitivity to decitabine\n* Known to be HIV-positive","healthyVolunteers":false,"sex":"ALL","minimumAge":"70 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival","description":"The distribution of overall survival was estimated by the method of Kaplan and Meier. A log-rank analysis stratified by randomization stratification factors was used to compare overall survival between Arm A (decitabine/sapacitabine) versus Arm C (decitabine). Cox proportional hazards models were used to identify predictive factors for overall survival.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Remission (CR)","description":"Normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, and bone marrow to \\<=5 % blasts; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\* independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"40","spread":null},{"groupId":"OG001","value":"26","spread":null}]},{"measurements":[{"groupId":"OG000","value":"198","spread":null},{"groupId":"OG001","value":"213","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Complete Remission With Incomplete Platelet Count Recovery (CRp)","description":"Normalization of bone marrow to \\<=5% blasts; peripheral neutrophils \\>=1000 /microliter, platelet \\<=100,000 /microliter within 2 weeks of bone marrow biopsy/aspirate; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"5","spread":null}]},{"measurements":[{"groupId":"OG000","value":"233","spread":null},{"groupId":"OG001","value":"234","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Partial Remission (PR)","description":"Normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, \\>=50% decrease in bone marrow blasts over pre-treatment but still \\>5%; independent of transfusions\\*\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"8","spread":null}]},{"measurements":[{"groupId":"OG000","value":"226","spread":null},{"groupId":"OG001","value":"231","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Hematological Improvement","description":"HI with duration (HI)\n\n1. Erythroid response (HI-E) for patients with pre-treatment hemoglobin \\< 11 g/dL; Major response: \\>2 g/dL increase in hemoglobin; for RBC, transfusion independence\\* Minor response: 1 to 2 g/dL increase in hemoglobin; for RBC, a 50% decrease in transfusion requirements\n2. Platelet response (HI-P) for pre-treatment platelet count \\<100,000/mm3; Major response: an absolute increase of platelet count by \\>=30,000/mm3; stabilization of platelet counts and platelet transfusion independence\\* Minor response: \\>=50% increase in platelet count with a net increase \\> 10,000/mm3 but \\<30,000/mm3\n3. Neutrophil response (HI-N) for absolute neutrophil count (ANC) \\< 1,500/mm3 before therapy; Major response: \\>=100% increase, or an absolute increase of \\>500/mm3, whichever is greater Minor response: \\>=100% increase, but absolute increase \\< 500/mm3\n\n   * independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"38","spread":null}]},{"measurements":[{"groupId":"OG000","value":"197","spread":null},{"groupId":"OG001","value":"201","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Stable Disease (SD)","description":"Failure to achieve at least hematologic improvement (HI), but no evidence of clinically significant progression for \\> 16 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"31","spread":null}]},{"measurements":[{"groupId":"OG000","value":"217","spread":null},{"groupId":"OG001","value":"208","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]},{"type":"SECONDARY","title":"Blood Products Transfused","description":"Number of units of packed red blood cells (PRBC) and/or platelet transfusions administered per 8-week period prior to the first dose of study drug and through the date of treatment discontinuation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"Hospitalized Days","description":"In-patient days in hospital.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]}]},{"type":"SECONDARY","title":"1-year Survival","description":"One-year survival is the percentage of patients who are alive at 1-year measured from the date of randomization.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Complete Remission (dCR)","description":"Durations of normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, and bone marrow to \\<=5 % blasts; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\* independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"10.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Complete Remission With Incomplete Platelet Count Recovery (dCRp)","description":"Duration of normalization of bone marrow to \\<=5% blasts; peripheral neutrophils \\>=1000 /microliter, platelet \\<=100,000 /microliter within 2 weeks of bone marrow biopsy/aspirate; independent of transfusions\\*; and no extramedullary leukemia.\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.5","spread":null},{"groupId":"OG001","value":"5.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Partial Remission (dPR)","description":"Duration of normalization of peripheral neutrophils to \\>=1000 /microliter, platelet to \\>=100,000/microliter within 2 weeks of bone marrow biopsy/aspirate, \\>=50% decrease in bone marrow blasts over pre-treatment but still \\>5%; independent of transfusions\\*\n\n\\*independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"1.9","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Hematological Improvement (dHI)","description":"Duration of HI\n\n1. Erythroid response (HI-E) for patients with pre-treatment hemoglobin \\< 11 g/dL; Major response: \\>2 g/dL increase in hemoglobin; for RBC, transfusion independence\\* Minor response: 1 to 2 g/dL increase in hemoglobin; for RBC, a 50% decrease in transfusion requirements\n2. Platelet response (HI-P) for pre-treatment platelet count \\<100,000/mm3; Major response: an absolute increase of platelet count by \\>=30,000/mm3; stabilization of platelet counts and platelet transfusion independence\\* Minor response: \\>=50% increase in platelet count with a net increase \\> 10,000/mm3 but \\<30,000/mm3\n3. Neutrophil response (HI-N) for absolute neutrophil count (ANC) \\< 1,500/mm3 before therapy; Major response: \\>=100% increase, or an absolute increase of \\>500/mm3, whichever is greater Minor response: \\>=100% increase, but absolute increase \\< 500/mm3\n\n   * independent of transfusions refer to no platelet transfusion for 1 week prior to achieving the response","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"4.8","spread":null}]}]}]},{"type":"SECONDARY","title":"Duration of Stable Disease (dSD)","description":"Failure to achieve at least hematologic improvement (HI), but no evidence of clinically significant progression for \\> 16 weeks.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23.3","spread":null},{"groupId":"OG001","value":"14.8","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":17,"n":21},"commonTop":["THROMBOCYTOPENIA","ANAEMIA","NEUTROPENIA","CONSTIPATION","NAUSEA"]}}}